Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model

Molecular Cancer Therapeutics

Volumn 11, Issue 3, 2012, Pages 752-762

  Pastuskovas, Cinthia V ^a   Mundo, Eduardo E ^a   Williams, Simon P ^a   Nayak, Tapan K ^b   Ho, Jason ^a   Ulufatu, Sheila ^a   Clark, Suzanna ^a   Ross, Sarajane ^a   Cheng, Eric ^a   Parsons Reponte, Kathryn ^a   Cain, Gary ^a   Van Hoy, Marjie ^a   Majidy, Nicholas ^a   Bheddah, Sheila ^a   Chuh, Josefa Dela Cruz ^a   Kozak, Katherine R ^a   Lewin Koh, Nicholas ^a   Nauka, Peter ^a   Bumbaca, Daniela ^a   Sliwkowski, Mark ^a   Tibbitts, Jay ^a   Theil, Frank Peter ^a   Fielder, Paul J ^a   Khawli, Leslie A ^a   Boswell, C Andrew ^a   more..

^a GENENTECH INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; AREA UNDER THE CURVE; ARTICLE; AUTORADIOGRAPHY; BREAST CANCER; CANCER MODEL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG PENETRATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MACROMOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR BLOOD FLOW; TUMOR XENOGRAFT; X RAY ANALYSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859156795     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0742-T     Document Type: Article

References (50)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57. (Pubitemid 41486396)
2. Pivot X, Bedairia N, Thiery-Vuillemin A, Espie M, Marty M. Combining molecular targeted therapies: clinical experience. Anticancer Drugs 2011;22:701-10.
3. Sundaresan S, Penuel E, Sliwkowski MX. The biology of human epidermal growth factor receptor 2. Curr Oncol Rep 1999;1:16-22.
4. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-9.
5. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51. (Pubitemid 47026733)
6. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
7. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12. (Pubitemid 19147683)
8. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998;3:237-52.
9. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26. (Pubitemid 34111379)
10. Romond EH, Perez EA, Bryant J, Suman VJ, GeyerCE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84. (Pubitemid 41464706)
11. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006;232:123-38. (Pubitemid 43170962)
12. Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 2002;29:29-37. (Pubitemid 34816063)
13. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76. (Pubitemid 36749215)
14. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27. (Pubitemid 46202320)
15. Crawford Y, Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci 2009;30:624-30.
16. Mordenti J, Thomsen K, Licko V, Chen H, Meng YG, Ferrara N. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol 1999;27:14-21. (Pubitemid 29075738)
17. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
18. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10:1706-16. (Pubitemid 38435562)
19. Emlet DR, Brown KA, Kociban DL, Pollice AA, Smith CA, Ong BB, et al. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther 2007;6:2664-74. (Pubitemid 350058147)
20. Friess T, Scheuer W, Hasmann M. Combinations of trastuzumab with either pertuzumab or bevacizumab show higher efficacy than lapatinib-based combinations against HER2-positive breast cancer xenografts progressing on trastuzumab monotherapy. AACR Meeting Abstracts 2007: Poster B102, Presented at the American Association of Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, California, October 22-26, 2007.
21. Scheuer W, Friess T, Hasmann M. Enhanced antitumour effect by combination of HER2-targeting antibodies with bevacizumab in a human breast cancer xenograft model (Poster 213). Eur J Cancer Suppl 2006;4:66.
22. Hurvitz S, Pegram M, Lin L, Chan D, Allen H, Dichmann R, et al. Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. Cancer Res 2009;69:6094.
23. BostromJ, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009;323:1610-4.
24. Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, et al. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 2008;7:3747-58.
25. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002;416:279-80. (Pubitemid 34260234)
26. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-30. (Pubitemid 27527914)
27. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
28. O'Connor JP, Carano RA, Clamp AR, Ross J, Ho CC, Jackson A, et al. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 2009;15:6674-82.
29. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765-70. (Pubitemid 26419043)
30. Yang AD, Bauer TW,CampER, Somcio R, Liu W, Fan F, et al. Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy. Cancer 2005;103:1561-70. (Pubitemid 40490016)
31. Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A 2007;104:3478-83.
32. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006;281:951-61.
33. Perera RM, Zoncu R, Johns TG, Pypaert M, Lee FT, Mellman I, et al. Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. Neoplasia 2007;9:1099-110. (Pubitemid 350255358)
34. Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer 1999;79:707-17. (Pubitemid 29082094)
35. Finkle D, Quan ZR, Asghari V, Kloss J, Ghaboosi N, Mai E, et al. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 2004;10:2499-511. (Pubitemid 38445712)
36. Chizzonite R, Truitt T, Podlaski FJ, Wolitzky AG, Quinn PM, Nunes P, et al. IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts. J Immunol 1991;147:1548-56.
37. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90.
38. Bagri A, Berry L, Gunter B, Singh M, Kasman I, Damico LA, et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res 2010;16:3887-900.
39. Boswell CA, Ferl GZ, Mundo EE, Bumbaca D, Schweiger MG, Theil FP, et al. Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow. PLoS One 2011;6:e17874.
40. Boswell CA, Ferl GZ, Mundo EE, Schweiger MG, Marik J, Reich MP, et al. Development and evaluation of a novel method for preclinical measurement of tissue vascular volume. Mol Pharm 2010;7:1848-57.
41. Pastuskovas CV, Mallet W, Clark S, Kenrick M, Majidy M, Schweiger M, et al. Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA125. Drug Metab Dispos 2010;38:2309-19.
42. Jaki T, Wolfsegger MJ, Ploner M. Confidence intervals for ratios of AUCs in the case of serial sampling: a comparison of seven methods. Pharm Stat 2009;8:12-24.
43. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
44. Michel RB, Ochakovskaya R, Mattes MJ. Rapid blood clearance of injected mouse IgG2a in SCID mice. Cancer Immunol Immunother 2002;51:547-56. (Pubitemid 35232004)
45. Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, et al. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997;38:1929-33. (Pubitemid 28030925)
46. 86Rb. Cancer Res 1974;34:1451-6.
47. Fukumura D, Yuan F, Endo M, Jain RK. Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyteendothelial interactions. Am J Pathol 1997;150:713-25. (Pubitemid 27073798)
48. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004;7:335-45. (Pubitemid 40767935)
49. Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci 2008;29:57-61.
50. Marty M, Pivot X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer 2008;44:912-20.